Thalidomide

規格

50-35-1CAS番号

200-031-1EC番号

2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dioneIUPAC名

C13H10N2O4化学式

258.23 g/mol分子量

thalidomide; 50-35-1; Thalomid; Contergan; Pantosediv; Distaval; Softenon; Kevadon; Calmorex; Neosedyn; Profarmil; Quetimid; Talimol; Telagan; Theophilcholine; Algosediv; Corronarobetin; Ectiluran; Enterosediv; Gastrinide; Nerosedyn; Neurosedin; Neurosedym; Noctosediv; Psycholiquid; Psychotablets; Quietoplex; Sandormin; Sedisperil; Shinnibrol; Telargean; Thalinette; Valgraine; Asmadion; Asmaval; Bonbrain; Calmore; Glutanon; Grippex; Hippuzon; Imidene; Neosydyn; Neurodyn; Nevrodyn; Noxodyn; Sedimide; Sleepan; Softenil; Tensival; Yodomin; Glupan; Isomin; Nibrol; Pangul; Sedin; Slipro; Thalin; Valgis; N-Phthaloylglutamimide; Predni-Sediv; Imida-lab; Sedalis sedi-lab; N-Phthalylglutamic acid imide; Neaufatin; Neurosedyn; Asidon 3; Pro-ban M; 3-Phthalimidoglutarimide; Imidan (peyta); Talidomida; Thaled; alpha-Phthalimidoglutarimide; Sedalis; (+-)-Thalidomide; NSC-66847; 2,6-Dioxo-3-phthalimidopiperidine; N-(2,6-Dioxo-3-piperidyl)phthalimide; Thalidomidum; Pharmion; Talidomide; Celgene; alpha-N-Phthalylglutaramide; Glutarimide, 2-phthalimido-; N-Phthalyl-glutaminsaeure-imid; alpha-(N-Phthalimido)glutarimide; Synovir; Myrin; DTXSID9022524; 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline; 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-; Phthalimide, N-(2,6-dioxo-3-piperidyl)-; 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione; 4Z8R6ORS6L; NSC-527179; 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; (+-)-N-(2,6-Dioxo-3-piperidyl)phthalimide; NSC66847; DTXCID402524; 2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione; Talidex; Sedoval K-17; RefChem:6298; CHEBI:9513; L04AX02; 2, 6-Dioxo-3-phthalimidopiperidine; 200-031-1; (+/-)-THALIDOMIDE; 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; Sedoval; Neufatin; Talargan; Talismol; Shin-naito S; K-17; Bonbrrin; Distaxal; Distoval; Kedavon; Thalidomide Celgene; K 17; .alpha.-Phthalimidoglutarimide; MFCD00153873; N-(2,6-dioxo-3-piperidinyl)phthalimide; .alpha.-N-Phthalylglutaramide; .alpha.-(N-Phthalimido)glutarimide; 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione; CHEMBL468; Thalidomide (soluble form); 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; ENMD 0995; Telargan; Thalomide; 2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione; Pro-Bam M; NCGC00015989-09; Talidomide [DCIT]; (+/-)-N-(2,6-dioxo-3-piperidyl)phthalimide; M02554; 1012310-87-0; Talidomida [INN-Spanish]; Thalidomidum [INN-Latin]; Thalidomine USP26; 2-(2,6-Dioxo-piperidin-3-yl)-isoindole-1,3-dione; Talizer; Phthalimide,6-dioxo-3-piperidyl)-; WLN: T56 BVNVJ C- DT6VMVTJ; Thalomid (TM); Thalomid (TN); Thalidomide Pharmion; Thaled (TN); N-Phthalyl-glutaminsaeure-imid [German]; N-Phthalimidoglutamic acid imide; HSDB 3586; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-; SR-01000076184; EINECS 200-031-1; UNII-4Z8R6ORS6L; NSC 527179; BRN 0030233; Talinol; Thalidomide (JAN/USP/INN); AI3-50606; CCRIS 8148; NSC-91730; (y)-Thalidomide; CAS-50-35-1; (?)-Thalidomide; Nphthaloylglutamimide; Prestwick_463; Thalidomide [USAN:USP:INN:BAN:JAN]; (A+/-)-Thalidomide; Pomalidomide Impurity O; Thalidomide (Standard); THALIDOMIDE [MI]; Prestwick0_000192; Prestwick1_000192; Prestwick2_000192; Prestwick3_000192; Spectrum2_000707; Spectrum3_001715; Spectrum4_001087; Spectrum5_001791; THALIDOMIDE [INN]; THALIDOMIDE [JAN]; (.+/-.)-Thalidomide; THALIDOMIDE [HSDB]; THALIDOMIDE [USAN]; UPCMLD-DP139; THALIDOMIDE [VANDF]; Thalomid (TN) (Celgene); SCHEMBL7581; NCIOpen2_003188; THALIDOMIDE [MART.]; Lopac0_001224; BSPBio_000143; BSPBio_001156; BSPBio_003330; KBioGR_000496; KBioGR_001474; KBioGR_002322; KBioSS_000496; KBioSS_002324; THALIDOMIDE [USP-RS]; THALIDOMIDE [WHO-DD]; MLS000069353; DivK1c_000051; SPECTRUM1503607; SPBio_000893; SPBio_002064; THALIDOMIDE [EMA EPAR]; BPBio1_000159; GTPL7327; orb1224909; orb1310829; SCHEMBL15197560; SCHEMBL23093380; SCHEMBL26641645; UPCMLD-DP139:001; CHEBI:74947; HMS500C13; KBio1_000051; KBio2_000496; KBio2_002322; KBio2_003064; KBio2_004890; KBio2_005632; KBio2_007458; KBio3_000911; KBio3_000912; KBio3_002550; KBio3_002802; THALIDOMIDE [ORANGE BOOK]; cMAP_000022; NINDS_000051; Bio1_000387; Bio1_000876; Bio1_001365; Bio2_000418; Bio2_000898; GLXC-07837; HMS1362J17; HMS1568H05; HMS1792J17; HMS1922E12; HMS1990J17; HMS2090O05; HMS2093G15; HMS2095H05; HMS2234C07; HMS3259C22; HMS3263F10; HMS3266F13; HMS3373E06; HMS3373G15; HMS3403J17; HMS3414F19; HMS3654A20; HMS3678F19; HMS3712H05; HMS3884I05; HMS5079O13; Pharmakon1600-01503607; THALIDOMIDE [USP MONOGRAPH]; NSC91729; NSC91730; Tox21_110275; Tox21_300580; Tox21_501224; 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, (+-)-; AC-917; BBL023439; BDBM50070114; CCG-39878; EBC-04403; HY-14658R; MSK157727; NSC527179; NSC758479; STL356025; ( inverted question mark)-Thalidomide; AKOS009529198; Tox21_110275_1; DB01041; FT15648; LP01224; NC00600; NSC-758479; SDCCGSBI-0051191.P004; (+/-)-Thalidomide, >=98%, powder; IDI1_000051; IDI1_002173; (+/-)-Thalidomide - Bio-X trade mark; NCGC00015989-03; NCGC00015989-04; NCGC00015989-05; NCGC00015989-06; NCGC00015989-07; NCGC00015989-08; NCGC00015989-10; NCGC00015989-11; NCGC00015989-12; NCGC00015989-13; NCGC00015989-14; NCGC00015989-16; NCGC00015989-17; NCGC00015989-26; NCGC00015989-29; NCGC00015989-32; NCGC00024708-02; NCGC00024708-03; NCGC00024708-04; NCGC00024708-05; NCGC00024708-06; NCGC00024708-07; NCGC00024708-08; NCGC00024708-09; NCGC00024708-10; NCGC00024708-11; NCGC00254343-01; NCGC00261909-01; AS-12367; BP-30256; BT164465; HY-14658; NCI60_023904; SMR000058524; SY052614; WLN: T56 BVNVJ C- DT6VMVTJ -D; WLN: T56 BVNVJ C- DT6VMVTJ -L; SBI-0051191.P003; DB-051759; Phthalimide,6-dioxo-3-piperidyl)-, (+)-; Phthalimide,6-dioxo-3-piperidyl)-, (-)-; AB00052362; EU-0101224; NS00009590; S1193; ST51039042; SW196678-4; T0213; EN300-60005; Phthalimide,6-dioxo-3-piperidyl)-, D-(+)-; Phthalimide,6-dioxo-3-piperidyl)-, L-(-)-; C07910; D00754; AB00052362-11; AB00052362-12; AB00052362-13; AB00052362_14; AB00052362_15; Thalidomide (Immunoprin, Contergan and Thalomid); N-(2,6-Dioxo-3-piperidinyl)phthalimide, racemic; Q203174; SR-01000076184-1; SR-01000076184-3; SR-01000076184-5; SR-01000076184-8; Thalidomide N-(2,6-Dioxopiperidin-3-yl)phthalimide; BRD-A93255169-001-04-4; BRD-A93255169-001-06-9; BRD-A93255169-001-24-2; BRD-A93255169-001-27-5; BRD-A93255169-001-28-3; Z905162656; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (R)-; 1H-Isoindole-1, 2-(2,6-dioxo-3-piperidinyl)-, (S)-; 2-(2,6-dioxoazaperhydroin-3-yl)benzo[c]azoline-1,3-dione; 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione #; [(R,S)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; Thalidomide, United States Pharmacopeia (USP) Reference Standard; ( inverted question mark)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione; 1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-, (+/-)-別名